Vertex Pharmaceuticals CEO Jeffrey Leiden's 2018 pay rises 9% to $19M
Vertex Pharmaceuticals reports 2018 executive compensation
By ExecPay News
Published: April 26, 2019
Vertex Pharmaceuticals reported fiscal year 2018 executive compensation information on April 26, 2019.
In 2018, seven executives at Vertex Pharmaceuticals received on average a compensation package of $6.9M, a 5% increase compared to previous year.
Average pay of disclosed executives at Vertex Pharmaceuticals
Jeffrey M. Leiden, Chief Executive Officer, received $19M in total, which increased by 9% compared to 2017. 52% of Leiden's compensation, or $9.8M, was in stock awards. Leiden also received $3.4M in non-equity incentive plan, $4.2M in option awards, $1.3M in salary, as well as $15K in other compensation.
For fiscal year 2018, the median employee pay was $232,178 at Vertex Pharmaceuticals. Therefore, the ratio of Jeffrey M. Leiden's pay to the median employee pay was 81 to one.
Jeffrey Chodakewitz, Chief Medical Officer, received a compensation package of $5.7M. 55% of the compensation package, or $3.2M, was in stock awards.
Amit Sachdev, EVP & Chief Regulatory Officer, earned $5.7M in 2018, a 16% increase compared to previous year.
Michael Parini, EVP & Chief Legal and Administrative Officer, received $5.4M in 2018, which decreases by 10% compared to 2017.
Stuart A. Arbuckle, EVP & Chief Commercial Officer, earned $5.3M in 2018, a 22% increase compared to previous year.
Ian F. Smith, Chief Financial Officer, received $4.6M in 2018, which decreases by 22% compared to 2017.
Thomas Graney, Chief Financial Officer, earned $2.9M in 2018, a 52% increase compared to previous year.
Related executives
Jeffrey Leiden
Vertex Pharmaceuticals
Chairman
Stuart Arbuckle
Vertex Pharmaceuticals
Chief Operating Officer
Michael Parini
Vertex Pharmaceuticals
EVP & Chief Legal and Administrative Officer
Amit Sachdev
Vertex Pharmaceuticals
EVP & Chief Patient Officer
Jeffrey Chodakewitz
Vertex Pharmaceuticals
Chief Medical Officer
Thomas Graney
Vertex Pharmaceuticals
Chief Financial Officer
Ian Smith
Vertex Pharmaceuticals
Chief Financial Officer
You may also like
Source: SEC filing on April 26, 2019.